เอกสารอ้างอิง
[1]. Carolyn B Becker, Adi Cohen. Epidemiology and etiology of premenopausal osteoporosis. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA; 2022 (Accessed on September 9, 2022).
[2]. Catherine Van Poznak, Daniel F Hayes, Sadhna R Vora. Use of osteoclast inhibitors in early breast cancer. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA; 2022 (Accessed on September 1, 2022).
[3]. Willium J., Benjamin O, Abraham J. et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline®) Breast cancer 2020. 5th ed: National Comprehensive Cancer Network.
[4]. MIMS Thailand. (2022). Zolennic infusion 4 mg/5 mL. In MIMS Online. https://www.mims.com/thailand/image/info/zolennic%20infusion%204%20mg-5%20ml/4%20mg-5%20ml?id=a1e1b9e2-228e-49a2-92e6-a08b0107f00c
[5]. Lexicomp, Inc. Zoledronic acid: Drug information. In:Post TW, ed.UpToDate.Waltham: UpToDate; 2022 (Accessed on September 1, 2022).
[6]. Zoledronic acid. In: In Depth Answers [database on the Internet]. Greenwood Village (CO): IBM Corporation; 2022 [cited 2022 September 9]. Available from: www.micromedexsolutions.com. Subscription required to view.
[7]. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003 October 15;98(8):1735-44.
[8]. Anagha PP, Sen S. The efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss for postmenopausal women with early breast cancer: a systematic review and meta-analysis. J Oncol. 2014;2014:625060.
[9]. Mei M, Xiang Z, Yang J, Xiang R. Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-analysis of 13 randomized controlled trials. Curr Probl Cancer. 2020 April;44(2):100507.